| Autor: |
Nozomi, Morikawa, Seiji, Yoshitomi, Kyoko, Hara, Asuka, Mimata, Hisashi, Tsuji |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Gan to kagaku ryoho. Cancerchemotherapy. 47(13) |
| ISSN: |
0385-0684 |
| Popis: |
We aimed to examine the effects of palbociclib and neutropenia in patients with metastatic breast cancer(MBC). From December 2017 to December 2019, 18 patients with estrogen receptor(ER)-positive, human epidermal growth factor receptor 2(HER2)-negative MBC were treated with palbociclib for at least 1 cycle. The most common adverse event(AE) was neutropenia, which occurred in 83% of all cases. With cessation and dose reduction, none of the patients had Grade 4 neutropenia. Palbociclib used in the first- or second-line treatment of MBC showed a higher efficacy than when used as the third-line treatment, which was observed as a longer duration to stay on treatment and higher efficacy. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
